{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:59:29Z","timestamp":1777496369034,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pathol.2022.02.006","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T04:35:41Z","timestamp":1652502941000},"page":"755-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-6155","authenticated-orcid":false,"given":"Geoffrey","family":"Kershaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-128X","authenticated-orcid":false,"given":"Caroline","family":"Dix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teh-Liane","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2022.02.006_bib1","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"Muller","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pathol.2022.02.006_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.02.006_bib3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2022.02.006_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.02.006_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.02.006_bib6","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.pathol.2022.02.006_bib7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A\u00a0Pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pathol.2022.02.006_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.pathol.2022.02.006_bib9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pathol.2022.02.006_bib10","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/ijlh.13114","article-title":"Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays","volume":"42","author":"Adamkewicz","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.pathol.2022.02.006_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A\u00a0first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.02.006_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"26","author":"Jenkins","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.pathol.2022.02.006_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hae.13001","article-title":"A\u00a0world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE","volume":"22","author":"Turecek","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.pathol.2022.02.006_bib14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2516.2010.02481.x","article-title":"International comparative field study of N8 evaluating factor VIII assay performance","volume":"17","author":"Viuff","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.pathol.2022.02.006_bib15","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1111\/hae.14038","article-title":"Australian comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein (Eloctate\u00ae)","volume":"26","author":"Kershaw","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.pathol.2022.02.006_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jth.13932","article-title":"International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories","volume":"16","author":"St Ledger","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pathol.2022.02.006_bib17","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1111\/hae.12925","article-title":"BAY 81-8973, a full-length recombinant factor VIII: results from an international comparative laboratory field study","volume":"22","author":"Kitchen","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.pathol.2022.02.006_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hae.12296","article-title":"Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories","volume":"20","author":"Sommer","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.pathol.2022.02.006_bib19","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/ijlh.13384","article-title":"Validation of the chromogenic Bethesda assay for FVIII inhibitors in hemophilia A patients receiving emicizumab","volume":"43","author":"Miller","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.pathol.2022.02.006_bib20","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3324\/haematol.2021.278579","article-title":"Non-inhibitory antibodies inducing increased emicizumab clearance in a severe hemophilia A inhibitor patient","volume":"106","author":"Harroche","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2022.02.006_bib21","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/jth.15506","article-title":"Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A","volume":"19","author":"Keneda","year":"2021","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T06:03:08Z","timestamp":1675576988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302522001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0031302522001313"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2022.02.006","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2022.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}